Sign up to save your podcasts
Or
Share 🧬 Risk, Recurrence, Relief: Apixaban's Edge in VTE 🌡️ Emphasizes the risk stratification, recurrence data, and therapeutic benefit
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
🧬 Risk, Recurrence, Relief: Apixaban's Edge in VTE 🌡️ Emphasizes the risk stratification, recurrence data, and therapeutic benefit
🩺 New Insights on Apixaban for VTE!
📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE.
📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding.
🎯 Editorial in NEJM urges a shift from binary labels ("provoked vs unprovoked") to a patient-centered, risk-adapted approach.
🧠 Art meets evidence in the decision to extend anticoagulation.
💬 Let's rethink how we label, risk-stratify, and treat.
📚 #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine #SharedDecisionMaking #EvidenceBasedMedicine #Cardiology
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
🩺 New Insights on Apixaban for VTE!
📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE.
📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding.
🎯 Editorial in NEJM urges a shift from binary labels ("provoked vs unprovoked") to a patient-centered, risk-adapted approach.
🧠 Art meets evidence in the decision to extend anticoagulation.
💬 Let's rethink how we label, risk-stratify, and treat.
📚 #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine #SharedDecisionMaking #EvidenceBasedMedicine #Cardiology
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
907 Listeners
The Curbsiders Internal Medicine Podcast
3,380 Listeners
The Mel Robbins Podcast
20,613 Listeners